secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2022-08-12T23:59:59+00:00
Accession:  0001818382-22-000103
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte Q2 net income $36.9M driven by non-cash gains; HAVs show promise in Ukraine
--------------------------------------------------------------------------------

- Cash $189.0M as of June 30, 2022; company expects runway through 2024, past potential HAV approval in vascular trauma.
- Net income $36.9M vs net loss $17.2M in Q2 2021; driven by $55.4M non-cash gain from contingent earnout remeasurement.
- Revenue $1.3M (grants), up from $0.7M; R&D expense $14.7M, G&A $5.2M.
- HAVs implanted in Ukraine under humanitarian initiative reportedly functioning and infection-free, saving limbs.
- Appointed Diane Seimetz to Board and Shamik Parikh as CMO; preclinical small-diameter HAV data in CABG presented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838222000103/0001818382-22-000103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838222000103/huma-20220812.htm
  HTML page:      https://secwatch.observer/filing/0001818382-22-000103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer